Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Constantijn H.J. Muselaers"'
Autor:
Umberto Carbonara, Daniele Amparore, Leonardo D. Borregales, Anna Caliò, Chiara Ciccarese, Pietro Diana, Selcuk Erdem, Laura Marandino, Michele Marchioni, Constantijn H.J. Muselaers, Carlotta Palumbo, Nicola Pavan, Angela Pecoraro, Eduard Roussel, Hannah Warren, Zhen-Jie Wu, Riccardo Campi, Riccardo Bertolo
Publikováno v:
Therapeutic Advances in Urology, Vol 15 (2023)
Single-port (SP) robotic surgery is a novel technology and is at the beginning of its adoption curve in urology. The goal of this narrative review is to provide an overview of SP-robotic partial nephrectomy (PN) 4 years after the introduction of the
Externí odkaz:
https://doaj.org/article/288ce7981ab5430c96b3a8d8576fa68e
Autor:
Umberto Carbonara, Daniele Amparore, Cosimo Gentile, Riccardo Bertolo, Selcuk Erdem, Alexandre Ingels, Michele Marchioni, Constantijn H.J. Muselaers, Onder Kara, Laura Marandino, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Fabio Crocerossa, Giuseppe Torre, Riccardo Campi, Pasquale Ditonno
Publikováno v:
Asian Journal of Urology, Vol 9, Iss 3, Pp 227-242 (2022)
Objective: No standard strategy for diagnosis and management of positive surgical margin (PSM) and local recurrence after partial nephrectomy (PN) are reported in literature. This review aims to provide an overview of the current strategies and furth
Externí odkaz:
https://doaj.org/article/cef652173ddb458b8b042241cf72a0bd
Autor:
Michele Marchioni, Daniele Amparore, Igino Andrea Magli, Riccardo Bertolo, Umberto Carbonara, Selcuk Erdem, Alexandre Ingels, Constantijn H.J. Muselaers, Onder Kara, Marco Mascitti, Tobias Klatte, Maximilian Kriegmair, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Laura Marandino, Riccardo Campi, Luigi Schips
Publikováno v:
Asian Journal of Urology, Vol 9, Iss 3, Pp 215-226 (2022)
Objective: The role of lymph node dissection (LND) is still controversial in patients with renal cell carcinoma undergoing surgery. We aimed to provide a comprehensive review of the literature about the effect of LND on survival, prognosis, surgical
Externí odkaz:
https://doaj.org/article/3b1a7e6211234421858aa69bb10ea49a
Autor:
Constantijn H.J. Muselaers, Egbert Oosterwijk, Desirée L. Bos, Wim J.G. Oyen, Peter F.A. Mulders, Otto C. Boerman
Publikováno v:
Molecular Imaging, Vol 13 (2014)
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) using anti-carbonic anhydrase IX (CAIX) antibody G250. To investigate the potential of RIT with lutetium 177 ( 177 Lu)-labeled G250, we conducted a prot
Externí odkaz:
https://doaj.org/article/86cfd2a6404e43cfa1c1897b4fc6d1a8
Autor:
James Nagarajah, J. Alfred Witjes, Martin Gotthardt, Jelle O. Barentsz, Sandra Heskamp, Jean-Paul A. van Basten, Diederik M. Somford, Robert J. Smeenk, Linda G.W. Kerkmeijer, Niven Mehra, Winald R. Gerritsen, J. Fred Verzijlbergen, Tom W.J. Scheenen, Annemarie Eek, Melline G.M. Schilham, Maike J.M. Uijen, Patrik Zámecnik, Mark W. Konijnenberg, J.P. Michiel Sedelaar, Marcel J.R. Janssen, Inge M. van Oort, Constantijn H.J. Muselaers, Steffie M.B. Peters, Bastiaan M. Privé
Purpose:[177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee5227f2482c2e8c0f3bed1c1ab3d53
https://doi.org/10.1158/1078-0432.c.6530696.v1
https://doi.org/10.1158/1078-0432.c.6530696.v1
Autor:
James Nagarajah, J. Alfred Witjes, Martin Gotthardt, Jelle O. Barentsz, Sandra Heskamp, Jean-Paul A. van Basten, Diederik M. Somford, Robert J. Smeenk, Linda G.W. Kerkmeijer, Niven Mehra, Winald R. Gerritsen, J. Fred Verzijlbergen, Tom W.J. Scheenen, Annemarie Eek, Melline G.M. Schilham, Maike J.M. Uijen, Patrik Zámecnik, Mark W. Konijnenberg, J.P. Michiel Sedelaar, Marcel J.R. Janssen, Inge M. van Oort, Constantijn H.J. Muselaers, Steffie M.B. Peters, Bastiaan M. Privé
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5752047a06c3325540f120e571753c90
https://doi.org/10.1158/1078-0432.22481447
https://doi.org/10.1158/1078-0432.22481447
Autor:
Walter Jentzen, Pedro Fragoso Costa, Marcel J.R. Janssen, Niven Mehra, Constantijn H.J. Muselaers, Regina Hofferber, Mark Konijnenberg, Maarten de Bakker, Martin Gotthardt, J. Alfred Witjes, Frank de Lange, Bastiaan M. Privé, James Nagarajah, Steffie M. B. Peters
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 49, 4, pp. 1101-1112
European Journal of Nuclear Medicine and Molecular Imaging, 49, 1101-1112
European Journal of Nuclear Medicine and Molecular Imaging, 49(4), 1101-1112. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 49, 1101-1112
European Journal of Nuclear Medicine and Molecular Imaging, 49(4), 1101-1112. Springer-Verlag
Introduction Patient eligibility for [177Lu]Lu-PSMA therapy remains a challenge, with only 40–60% response rate when patient selection is done based on the lesion uptake (SUV) on [68Ga]Ga-PSMA-PET/CT. Prediction of absorbed dose based on this pre-t
Autor:
Martin Gotthardt, J. Fred Verzijlbergen, Jean-Paul A. van Basten, Melline G.M. Schilham, James Nagarajah, Robert Jan Smeenk, Sandra Heskamp, J. Alfred Witjes, Steffie M. B. Peters, Tom W. J. Scheenen, Marcel J.R. Janssen, Inge M. van Oort, Maike J. M. Uijen, Jelle O. Barentsz, Niven Mehra, Michiel Sedelaar, Bastiaan M. Privé, Diederik M. Somford, Constantijn H.J. Muselaers, Annemarie Eek, Winald R. Gerritsen, Linda G W Kerkmeijer, Mark Konijnenberg, Patrik Zamecnik
Publikováno v:
Clinical Cancer Research, 27, 13, pp. 3595-3601
Clinical Cancer Research, 27, 3595-3601
Clinical Cancer Research, 27(13), 3595-3601. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 3595-3601
Clinical Cancer Research, 27(13), 3595-3601. American Association for Cancer Research Inc.
Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA
Autor:
Maarten de Bakker, Martin Gotthardt, Bastiaan M. Privé, Walter Jentzen, Mark Konijnenberg, Annemarie Eek, Steffie M. B. Peters, J. Alfred Witjes, Frank de Lange, James Nagarajah, Constantijn H.J. Muselaers, Niven Mehra
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 49, 2, pp. 460-469
European Journal of Nuclear Medicine and Molecular Imaging, 49, 460-469
European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 460-469. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 49, 460-469
European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 460-469. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging
Introduction While [177Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f2ba65d5e6054957e9b82b1376f081
https://repository.ubn.ru.nl/handle/2066/248282
https://repository.ubn.ru.nl/handle/2066/248282
Autor:
Willemijn A. M. van Gemert, Andries M. Bergman, Constantijn H.J. Muselaers, Henk G. van der Poel, Walter Noordzij, André N. Vis, Patrik Zamecnik, Bastiaan M. Privé, Harm Westdorp, Inge M. van Oort, Michel de Groot, James Nagarajah, Martin Gotthardt, Marianne A. Jonker, Winald R. Gerritsen, Daniela E. Oprea-Lager, Niven Mehra, Wouter V. Vogel, Marcel J.R. Janssen, Jelle O. Barentsz, J. Alfred Witjes, J. Fred Verzijlbergen, Tom W. J. Scheenen
Publikováno v:
Trials, 22, 1
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free surviv